<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="doi: 10.3390/molecules25040942molecules-25-00942 : Review Synthetic Compounds with 2-Amino-1,3,4-Thiadiazole Moiety Against" exact="Viral" post="Infections https://orcid.org/0000-0002-2926-0995SerbanGeorgeta CartaAntonioAcademic Editor[], getaserban_2000@yahoo.comepub: 2020-2-2collection: 2020-2254942received: 2020-1-29accepted: 2020-2-18(C)"/>
 <result pre="10.3390/molecules25040942molecules-25-00942 : Review Synthetic Compounds with 2-Amino-1,3,4-Thiadiazole Moiety Against Viral" exact="Infections" post="https://orcid.org/0000-0002-2926-0995SerbanGeorgeta CartaAntonioAcademic Editor[], getaserban_2000@yahoo.comepub: 2020-2-2collection: 2020-2254942received: 2020-1-29accepted: 2020-2-18(C) ,"/>
 <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Viral" post="infections have resulted in millions of victims in human"/>
 <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Viral" exact="infections" post="have resulted in millions of victims in human history."/>
 <result pre="effective medication, there are still no drugs that truly cure" exact="viral" post="infections. There are currently approximately 90 drugs approved for"/>
 <result pre="currently approximately 90 drugs approved for the treatment of human" exact="viral" post="infections. As resistance toward available antiviral drugs has become"/>
 <result pre="moiety that has been evaluated for antiviral activity against several" exact="viral" post="strains and could be considered possible prototypes for the"/>
 <result pre="possible prototypes for the development of new antiviral drugs. 2-amino-1,3,4-thiadiazole" exact="viral" post="infections antiviral agents drug resistance inhibitory concentration mechanism of"/>
 <result pre="prototypes for the development of new antiviral drugs. 2-amino-1,3,4-thiadiazole viral" exact="infections" post="antiviral agents drug resistance inhibitory concentration mechanism of action"/>
 <result pre="agents drug resistance inhibitory concentration mechanism of action 1. Human" exact="Viral" post="Infections Viruses are the smallest among all self-replicating organisms"/>
 <result pre="drug resistance inhibitory concentration mechanism of action 1. Human Viral" exact="Infections" post="Viruses are the smallest among all self-replicating organisms and"/>
 <result pre="in human populations [1]. There are broad types of human" exact="infections" post="caused by viruses, such as respiratory infections (common cold,"/>
 <result pre="broad types of human infections caused by viruses, such as" exact="respiratory" post="infections (common cold, Influenza), digestive infections (viral gastroenteritis), central"/>
 <result pre="types of human infections caused by viruses, such as respiratory" exact="infections" post="(common cold, Influenza), digestive infections (viral gastroenteritis), central nervous"/>
 <result pre="by viruses, such as respiratory infections (common cold, Influenza), digestive" exact="infections" post="(viral gastroenteritis), central nervous system infections (viral meningitis, viral"/>
 <result pre="as respiratory infections (common cold, Influenza), digestive infections (viral gastroenteritis)," exact="central nervous system" post="infections (viral meningitis, viral encephalitis), skin or mucosal infections"/>
 <result pre="(common cold, Influenza), digestive infections (viral gastroenteritis), central nervous system" exact="infections" post="(viral meningitis, viral encephalitis), skin or mucosal infections (herpes,"/>
 <result pre="digestive infections (viral gastroenteritis), central nervous system infections (viral meningitis," exact="viral" post="encephalitis), skin or mucosal infections (herpes, measles, mumps, smallpox"/>
 <result pre="nervous system infections (viral meningitis, viral encephalitis), skin or mucosal" exact="infections" post="(herpes, measles, mumps, smallpox and rubella), hepatic infections (hepatitis"/>
 <result pre="meningitis, viral encephalitis), skin or mucosal infections (herpes, measles, mumps," exact="smallpox" post="and rubella), hepatic infections (hepatitis A, B, C, E),"/>
 <result pre="or mucosal infections (herpes, measles, mumps, smallpox and rubella), hepatic" exact="infections" post="(hepatitis A, B, C, E), blood infections (acquired immunodeficiency"/>
 <result pre="and rubella), hepatic infections (hepatitis A, B, C, E), blood" exact="infections" post="(acquired immunodeficiency syndrome) and hemorrhagic fever (yellow fever, Ebola"/>
 <result pre="hepatic infections (hepatitis A, B, C, E), blood infections (acquired" exact="immunodeficiency" post="syndrome) and hemorrhagic fever (yellow fever, Ebola hemorrhagic fever)."/>
 <result pre="and this is the reason for the high incidence of" exact="viral" post="infections [2]. In addition, some viruses are etiological agents"/>
 <result pre="this is the reason for the high incidence of viral" exact="infections" post="[2]. In addition, some viruses are etiological agents in"/>
 <result pre="are etiological agents in the development of human tumors, particularly" exact="cervical cancer" post="and hepatic cancer [3]. The main method and most"/>
 <result pre="etiological agents in the development of human tumors, particularly cervical" exact="cancer" post="and hepatic cancer [3]. The main method and most"/>
 <result pre="in the development of human tumors, particularly cervical cancer and" exact="hepatic cancer" post="[3]. The main method and most cost-effective strategy for"/>
 <result pre="the development of human tumors, particularly cervical cancer and hepatic" exact="cancer" post="[3]. The main method and most cost-effective strategy for"/>
 <result pre="[3]. The main method and most cost-effective strategy for preventing" exact="viral" post="infections is through vaccination, which is meant to prevent"/>
 <result pre="The main method and most cost-effective strategy for preventing viral" exact="infections" post="is through vaccination, which is meant to prevent outbreaks"/>
 <result pre="increasing immunity [4]. Vaccines for the prevention of several common" exact="acute" post="viral infections, such as polio, rubella, measles, mumps, Influenza,"/>
 <result pre="immunity [4]. Vaccines for the prevention of several common acute" exact="viral" post="infections, such as polio, rubella, measles, mumps, Influenza, yellow"/>
 <result pre="acute viral infections, such as polio, rubella, measles, mumps, Influenza," exact="yellow fever," post="encephalitis, rabies, smallpox and hepatitis B were developed during"/>
 <result pre="as polio, rubella, measles, mumps, Influenza, yellow fever, encephalitis, rabies," exact="smallpox" post="and hepatitis B were developed during the 20th century"/>
 <result pre="rubella, measles, mumps, Influenza, yellow fever, encephalitis, rabies, smallpox and" exact="hepatitis" post="B were developed during the 20th century and are"/>
 <result pre="to develop safe and effective vaccines against viruses that cause" exact="chronic" post="infections, such as human immunodeficiency virus or hepatitis C"/>
 <result pre="vaccines against viruses that cause chronic infections, such as human" exact="immunodeficiency" post="virus or hepatitis C virus did not give the"/>
 <result pre="that cause chronic infections, such as human immunodeficiency virus or" exact="hepatitis" post="C virus did not give the expected results [1,4,5]."/>
 <result pre="virus did not give the expected results [1,4,5]. For many" exact="viral" post="infections, only symptomatic treatment is indicated, while it is"/>
 <result pre="give the expected results [1,4,5]. For many viral infections, only" exact="symptomatic" post="treatment is indicated, while it is expected the immune"/>
 <result pre="the virus. However, there are high-virulence viruses that cause serious" exact="viral" post="infections where antiviral treatment is essential for patient survival."/>
 <result pre="virus. However, there are high-virulence viruses that cause serious viral" exact="infections" post="where antiviral treatment is essential for patient survival. Although"/>
 <result pre="effective medication, there are still no drugs that truly cure" exact="viral" post="infections. Moreover, due to the ability of viruses to"/>
 <result pre="drugs approved for use in the treatment of nine human" exact="viral" post="infections caused by human immunodeficiency virus (HIV), hepatitis B"/>
 <result pre="approved for use in the treatment of nine human viral" exact="infections" post="caused by human immunodeficiency virus (HIV), hepatitis B virus"/>
 <result pre="the treatment of nine human viral infections caused by human" exact="immunodeficiency" post="virus (HIV), hepatitis B virus (HBV), hepatitis C virus"/>
 <result pre="nine human viral infections caused by human immunodeficiency virus (HIV)," exact="hepatitis" post="B virus (HBV), hepatitis C virus (HCV), herpes simplex"/>
 <result pre="caused by human immunodeficiency virus (HIV), hepatitis B virus (HBV)," exact="hepatitis" post="C virus (HCV), herpes simplex virus (HSV), Influenza virus,"/>
 <result pre="virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV)," exact="herpes" post="simplex virus (HSV), Influenza virus, human cytomegalovirus (HCMV), varicella-zoster"/>
 <result pre="virus (HSV), Influenza virus, human cytomegalovirus (HCMV), varicella-zoster virus (VZV)," exact="respiratory" post="syncytial virus (RSV) and human papillomavirus [18]. Most of"/>
 <result pre="antiviral activity. 3. The Activity of 2-Amino-1,3,4-Thiadiazole Derivatives Against Human" exact="Viral" post="Pathogens 3.1. Human Immunodeficiency Virus (HIV) About 37 million"/>
 <result pre="Activity of 2-Amino-1,3,4-Thiadiazole Derivatives Against Human Viral Pathogens 3.1. Human" exact="Immunodeficiency" post="Virus (HIV) About 37 million people infected with human"/>
 <result pre="Immunodeficiency Virus (HIV) About 37 million people infected with human" exact="immunodeficiency" post="virus (HIV) (Retroviridae family) were reported in 2016 [45],"/>
 <result pre="were reported in 2016 [45], with the highest incidence of" exact="infection" post="in sub-Saharan Africa. In the Third World, HIV infection"/>
 <result pre="incidence of infection in sub-Saharan Africa. In the Third World," exact="HIV infection" post="coupled with tropical diseases, malaria and tuberculosis causes a"/>
 <result pre="of infection in sub-Saharan Africa. In the Third World, HIV" exact="infection" post="coupled with tropical diseases, malaria and tuberculosis causes a"/>
 <result pre="In the Third World, HIV infection coupled with tropical diseases," exact="malaria" post="and tuberculosis causes a high level of mortality. Due"/>
 <result pre="Third World, HIV infection coupled with tropical diseases, malaria and" exact="tuberculosis" post="causes a high level of mortality. Due to sexual"/>
 <result pre="causes a high level of mortality. Due to sexual transmission," exact="acquired" post="immunodeficiency syndrome (AIDS) affects many young workers and therefore"/>
 <result pre="a high level of mortality. Due to sexual transmission, acquired" exact="immunodeficiency" post="syndrome (AIDS) affects many young workers and therefore the"/>
 <result pre="high level of mortality. Due to sexual transmission, acquired immunodeficiency" exact="syndrome" post="(AIDS) affects many young workers and therefore the disease"/>
 <result pre="immunodeficiency syndrome (AIDS) affects many young workers and therefore the" exact="disease" post="has not only a social impact, but also a"/>
 <result pre="is an essential enzyme that converts single-stranded RNA from the" exact="viral" post="genome into double-stranded DNA before its integration into host"/>
 <result pre="low cytotoxicity, NNRTIs have gained an increasingly important role in" exact="HIV infection" post="therapy [49]. Five drugs in the class of NNRTIs"/>
 <result pre="cytotoxicity, NNRTIs have gained an increasingly important role in HIV" exact="infection" post="therapy [49]. Five drugs in the class of NNRTIs"/>
 <result pre="activity and immunological effects similar to efavirenz with significantly fewer" exact="central nervous system" post="adverse events [54]. In January 2018, US Food and"/>
 <result pre="lead to drug resistance due to rapid mutations in the" exact="viral" post="genome resulting in RT mutations and HIV chemotherapy failure"/>
 <result pre="the limitations of currently available agents for the treatment of" exact="HIV infection" post="[46,59]. As a bioisostere of pyrimidine, a nucleoside component"/>
 <result pre="limitations of currently available agents for the treatment of HIV" exact="infection" post="[46,59]. As a bioisostere of pyrimidine, a nucleoside component"/>
 <result pre="activity of 1,3,4-thiadiazole derivatives often gave compounds with moderate or" exact="lower" post="in vitro anti-HIV-1 and anti-HIV-2 activity than the reference"/>
 <result pre="index SI ≤ 1 (SI = CC50/EC50). Other derivatives showed" exact="lower" post="activity with EC50 within the range of 47.4–125 μg/mL."/>
 <result pre="Even though anti-HIV activity and selectivity of derivative 6 are" exact="limited" post="compared to efavirenz (EC50 value of 0.003 μg/mL and"/>
 <result pre="against HIV-1 (strain IIIB) replication in MT-4 cell culture was" exact="lower" post="than that of zidovudine. However, given the butterfly-like orientation"/>
 <result pre="47 μM), the activity of the other compounds was even" exact="lower" post="(EC50 values &amp;gt; 70 μM) proving that substitution with"/>
 <result pre="to compounds with improved activity [64]. The invasion of the" exact="central nervous system" post="(CNS) by the HIV-1 virus frequently causes brain inflammation"/>
 <result pre="central nervous system (CNS) by the HIV-1 virus frequently causes" exact="brain inflammation" post="and progressive neurological diseases, which are commonly referred to"/>
 <result pre="HAND affects 7%–15% of AIDS patients and is characterized by" exact="neuronal" post="dysfunction including synaptic damage, neuronal degeneration and cell dropout"/>
 <result pre="patients and is characterized by neuronal dysfunction including synaptic damage," exact="neuronal" post="degeneration and cell dropout [72]. Cells involved in HAND"/>
 <result pre="macrophages and microglia, which are the main targets of HIV-1" exact="infection" post="in the brain. When infected with HIV-1, macrophages and"/>
 <result pre="release of several soluble neurotoxic factors, such as glutamate, inducing" exact="neuronal" post="damage [71]. Glutamine is the most abundant amino acid"/>
 <result pre="different physiologic processes, elevated extracellular concentrations of glutamate can induce" exact="neuronal" post="damage (e.g., dementia, brain atrophy) [71,72]. Some glutaminase inhibitors"/>
 <result pre="inhibited by various inhibitors, HIV-induced glutamate production decreased and the" exact="neuronal" post="damage was diminished [71,72,78]. Furthermore, for some glutaminase inhibitors,"/>
 <result pre="therapeutic target for the treatment of neurocognitive disorders associated with" exact="HIV infection" post="[71,72,78]. In connection with these results, a large number"/>
 <result pre="target for the treatment of neurocognitive disorders associated with HIV" exact="infection" post="[71,72,78]. In connection with these results, a large number"/>
 <result pre="were synthesized as a method of treating or preventing multiple" exact="viral" post="infections, including infections with retroviruses [75]. Multiple experiments were"/>
 <result pre="a method of treating or preventing multiple viral infections, including" exact="infections" post="with retroviruses [75]. Multiple experiments were performed in order"/>
 <result pre="or preventing multiple viral infections, including infections with retroviruses [75]." exact="Multiple" post="experiments were performed in order to study the biological"/>
 <result pre="acid virus that infects people of all ages [79,80]. HCMV" exact="infection" post="can be acquired through horizontal and vertical transmission. HCMV"/>
 <result pre="infects people of all ages [79,80]. HCMV infection can be" exact="acquired" post="through horizontal and vertical transmission. HCMV spreads from infected"/>
 <result pre="of all ages [79,80]. HCMV infection can be acquired through" exact="horizontal" post="and vertical transmission. HCMV spreads from infected people through"/>
 <result pre="the virus, such as urine, saliva, cervicovaginal secretions, sperm and" exact="breast" post="milk. Vertical transmission through organ transplantation, from mother to"/>
 <result pre="child or transmission via blood transfusion, is also possible [79,80]." exact="Blood" post="tests indicate that 60%–90% of the adult population experienced"/>
 <result pre="also possible [79,80]. Blood tests indicate that 60%–90% of the" exact="adult" post="population experienced HCMV infection at some time during their"/>
 <result pre="tests indicate that 60%–90% of the adult population experienced HCMV" exact="infection" post="at some time during their life [81]. Although most"/>
 <result pre="some time during their life [81]. Although most of these" exact="infections" post="are asymptomatic, certain patient groups such as babies that"/>
 <result pre="[79,82]. The first-line drugs recommended for the treatment of HCMV" exact="infection" post="are intravenous ganciclovir or orally administered valganciclovir [83]. Although"/>
 <result pre="is acceptable, hematological or neurological side effects can occur. Neutropenia," exact="thrombocytopenia" post="and anemia are the main toxic effects that limit"/>
 <result pre="hematological or neurological side effects can occur. Neutropenia, thrombocytopenia and" exact="anemia" post="are the main toxic effects that limit therapy with"/>
 <result pre="during ganciclovir therapy, which requires monitoring of renal function [84]." exact="Encephalopathy" post="is the neurotoxic effect of ganciclovir and valganciclovir [85]."/>
 <result pre="inhibitory activity against HCMV polymerase, their antiviral activity cannot be" exact="limited" post="to a specific mechanism of action. These compounds may"/>
 <result pre="experiments, many of these compounds also showed activity against other" exact="herpes" post="viruses, such as varicella-zoster virus (VZV), Epstein–Barr virus (EBV),"/>
 <result pre="herpes viruses, such as varicella-zoster virus (VZV), Epstein–Barr virus (EBV)," exact="herpes" post="simplex virus (HSV), and human herpesvirus type 8 (HHV-8)."/>
 <result pre="Epstein–Barr virus (EBV), herpes simplex virus (HSV), and human herpesvirus" exact="type 8" post="(HHV-8). Pharmaceutical compositions containing such compounds or their pharmaceutically"/>
 <result pre="on the purpose of their use to treat internal or" exact="external" post="viral infections [86]. 3.3. Respiratory Viruses Acute respiratory infections"/>
 <result pre="the purpose of their use to treat internal or external" exact="viral" post="infections [86]. 3.3. Respiratory Viruses Acute respiratory infections are"/>
 <result pre="purpose of their use to treat internal or external viral" exact="infections" post="[86]. 3.3. Respiratory Viruses Acute respiratory infections are a"/>
 <result pre="use to treat internal or external viral infections [86]. 3.3." exact="Respiratory" post="Viruses Acute respiratory infections are a major global health"/>
 <result pre="treat internal or external viral infections [86]. 3.3. Respiratory Viruses" exact="Acute" post="respiratory infections are a major global health problem responsible"/>
 <result pre="internal or external viral infections [86]. 3.3. Respiratory Viruses Acute" exact="respiratory" post="infections are a major global health problem responsible for"/>
 <result pre="or external viral infections [86]. 3.3. Respiratory Viruses Acute respiratory" exact="infections" post="are a major global health problem responsible for about"/>
 <result pre="for about 3.9 million deaths worldwide each year [87,88]. These" exact="infections" post="are of the top five causes of mortality worldwide"/>
 <result pre="under five years of age in many developing countries [87,89]." exact="Acute" post="respiratory infections are most often caused by viruses. Over"/>
 <result pre="five years of age in many developing countries [87,89]. Acute" exact="respiratory" post="infections are most often caused by viruses. Over 200"/>
 <result pre="years of age in many developing countries [87,89]. Acute respiratory" exact="infections" post="are most often caused by viruses. Over 200 viral"/>
 <result pre="respiratory infections are most often caused by viruses. Over 200" exact="viral" post="serotypes are associated with human respiratory diseases [90] including"/>
 <result pre="by viruses. Over 200 viral serotypes are associated with human" exact="respiratory" post="diseases [90] including Influenza A and Influenza B virus,"/>
 <result pre="respiratory diseases [90] including Influenza A and Influenza B virus," exact="respiratory" post="syncytial virus (RSV), parainfluenza virus (PIV), human adenovirus (HAdV),"/>
 <result pre="(HPyV), KIPyV and WUPyV, have been detected in patients with" exact="respiratory" post="infections [91]. These infections affect all age groups, but"/>
 <result pre="KIPyV and WUPyV, have been detected in patients with respiratory" exact="infections" post="[91]. These infections affect all age groups, but nearly"/>
 <result pre="have been detected in patients with respiratory infections [91]. These" exact="infections" post="affect all age groups, but nearly all severe episodes"/>
 <result pre="elderly and immunocompromised individuals (e.g., HIV-infected patients) [87,89]. In adults," exact="viral" post="respiratory infections are the cause of 30%–50% of pneumonia"/>
 <result pre="and immunocompromised individuals (e.g., HIV-infected patients) [87,89]. In adults, viral" exact="respiratory" post="infections are the cause of 30%–50% of pneumonia cases,"/>
 <result pre="immunocompromised individuals (e.g., HIV-infected patients) [87,89]. In adults, viral respiratory" exact="infections" post="are the cause of 30%–50% of pneumonia cases, 80%"/>
 <result pre="adults, viral respiratory infections are the cause of 30%–50% of" exact="pneumonia" post="cases, 80% of asthma complications and 20%–60% of chronic"/>
 <result pre="are the cause of 30%–50% of pneumonia cases, 80% of" exact="asthma" post="complications and 20%–60% of chronic obstructive pulmonary disease exacerbations"/>
 <result pre="of pneumonia cases, 80% of asthma complications and 20%–60% of" exact="chronic" post="obstructive pulmonary disease exacerbations [87]. Consequently, common viral respiratory"/>
 <result pre="cases, 80% of asthma complications and 20%–60% of chronic obstructive" exact="pulmonary disease" post="exacerbations [87]. Consequently, common viral respiratory infections cause a"/>
 <result pre="80% of asthma complications and 20%–60% of chronic obstructive pulmonary" exact="disease" post="exacerbations [87]. Consequently, common viral respiratory infections cause a"/>
 <result pre="20%–60% of chronic obstructive pulmonary disease exacerbations [87]. Consequently, common" exact="viral" post="respiratory infections cause a greater economic burden than many"/>
 <result pre="of chronic obstructive pulmonary disease exacerbations [87]. Consequently, common viral" exact="respiratory" post="infections cause a greater economic burden than many other"/>
 <result pre="chronic obstructive pulmonary disease exacerbations [87]. Consequently, common viral respiratory" exact="infections" post="cause a greater economic burden than many other clinical"/>
 <result pre="[87,92]. The World Health Organization has supported the monitoring of" exact="acute" post="respiratory diseases worldwide since 1977 [91]. The Influenza virus"/>
 <result pre="The World Health Organization has supported the monitoring of acute" exact="respiratory" post="diseases worldwide since 1977 [91]. The Influenza virus belongs"/>
 <result pre="The Influenza virus belongs to the Orthomyxoviridae family and causes" exact="respiratory" post="infections in about 20% of the global population every"/>
 <result pre="Influenza virus belongs to the Orthomyxoviridae family and causes respiratory" exact="infections" post="in about 20% of the global population every year."/>
 <result pre="in Asia in 2004–2005 due to the H5N1 strain of" exact="avian flu" post="[93]. The 2009 flu pandemic (swine flu) was the"/>
 <result pre="avian and swine [7,94]. The chemotherapy or prophylaxis of Influenza" exact="infections" post="comprises agents blocking the Influenza A virus M2 proton-selective"/>
 <result pre="This is increasingly recognized as a relevant approach to combat" exact="viral" post="resistance and provides broad-spectrum antiviral agents [95,96]. Many studies"/>
 <result pre="synthesized 2-phenylamino-1,3,4-thiadiazole derivatives 45–48 [49]. The antiviral activity against some" exact="respiratory" post="viruses such as Influenza A H1N1, Influenza A H3N2,"/>
 <result pre="favors antiviral activity on these strains (Figure 5) [49]. 3.4." exact="Hepatitis" post="Viruses Viral hepatitis is a liver inflammation responsible for"/>
 <result pre="activity on these strains (Figure 5) [49]. 3.4. Hepatitis Viruses" exact="Viral hepatitis" post="is a liver inflammation responsible for about 171,000 deaths"/>
 <result pre="on these strains (Figure 5) [49]. 3.4. Hepatitis Viruses Viral" exact="hepatitis" post="is a liver inflammation responsible for about 171,000 deaths"/>
 <result pre="(Figure 5) [49]. 3.4. Hepatitis Viruses Viral hepatitis is a" exact="liver inflammation" post="responsible for about 171,000 deaths every year in the"/>
 <result pre="every year in the European Region. Patients may have an" exact="acute" post="form as a recent infection, with relatively rapid onset"/>
 <result pre="as a recent infection, with relatively rapid onset or a" exact="chronic" post="form. There are five main hepatitis viruses (HAV, HBV,"/>
 <result pre="rapid onset or a chronic form. There are five main" exact="hepatitis" post="viruses (HAV, HBV, HCV, HDV and HEV) with different"/>
 <result pre="different impact on human health [97]. While HAV or HEV" exact="infection" post="is usually mild, with most people recovering quickly and"/>
 <result pre="is usually mild, with most people recovering quickly and completely," exact="infection" post="with HBV, HCV or HDV often leads to chronic"/>
 <result pre="completely, infection with HBV, HCV or HDV often leads to" exact="chronic" post="infections and progressive liver damage with the development of"/>
 <result pre="infection with HBV, HCV or HDV often leads to chronic" exact="infections" post="and progressive liver damage with the development of cirrhosis"/>
 <result pre="chronic infections and progressive liver damage with the development of" exact="cirrhosis" post="and liver cancer [97]. There are about 15 million"/>
 <result pre="and progressive liver damage with the development of cirrhosis and" exact="liver cancer" post="[97]. There are about 15 million people living with"/>
 <result pre="progressive liver damage with the development of cirrhosis and liver" exact="cancer" post="[97]. There are about 15 million people living with"/>
 <result pre="cancer [97]. There are about 15 million people living with" exact="chronic" post="HBV infection and about 14 million with HCV infection"/>
 <result pre="There are about 15 million people living with chronic HBV" exact="infection" post="and about 14 million with HCV infection in the"/>
 <result pre="with chronic HBV infection and about 14 million with HCV" exact="infection" post="in the European Region [97]. Safe and effective vaccines"/>
 <result pre="[97]. Safe and effective vaccines for the prevention of HBV" exact="infection" post="have been available since the 1990s. These vaccines also"/>
 <result pre="Many patients infected with HBV are adults born before the" exact="hepatitis" post="B vaccine became available in the 1990s. In these"/>
 <result pre="grazoprevir, elbasvir, ledipasvir, sofosbuvir, telaprevir) are in use [3,99] and" exact="chronic" post="infections with HBV and HCV can be currently controlled"/>
 <result pre="elbasvir, ledipasvir, sofosbuvir, telaprevir) are in use [3,99] and chronic" exact="infections" post="with HBV and HCV can be currently controlled or"/>
 <result pre="even cured. Due to the costs of antiviral drugs for" exact="chronic hepatitis," post="access to treatment is a major obstacle in many"/>
 <result pre="The derivative 49 was tested for antiviral activity against the" exact="hepatitis" post="B virus (HBV) using HepG2.2.2.15 cell line, a human"/>
 <result pre="hepatitis B virus (HBV) using HepG2.2.2.15 cell line, a human" exact="hepatoblastoma" post="cell line that produces HBV viral particles. Cytotoxicity was"/>
 <result pre="cell line, a human hepatoblastoma cell line that produces HBV" exact="viral" post="particles. Cytotoxicity was also tested by the cell viability"/>
 <result pre="promising scaffold in promoting anti-HBV activity [6]. 3.5. Miscellaneous Viruses" exact="Sindbis fever," post="a less common human viral disease, is caused by"/>
 <result pre="[6]. 3.5. Miscellaneous Viruses Sindbis fever, a less common human" exact="viral" post="disease, is caused by a mosquito-borne virus called Sindbis"/>
 <result pre="virus (Togaviridae family). Despite the wide distribution of Sindbis virus," exact="symptomatic" post="infections in humans have been reported in only a"/>
 <result pre="(Togaviridae family). Despite the wide distribution of Sindbis virus, symptomatic" exact="infections" post="in humans have been reported in only a few"/>
 <result pre="infections in humans have been reported in only a few" exact="limited" post="geographical areas such as northern Europe (Finland, Sweden and"/>
 <result pre="derivatives 50 (methyl) and 51 (allyl) showed antiviral activity against" exact="herpes" post="simplex virus-1 TK-KOS and herpes simplex virus-1 TK-KOS ACV,"/>
 <result pre="(allyl) showed antiviral activity against herpes simplex virus-1 TK-KOS and" exact="herpes" post="simplex virus-1 TK-KOS ACV, Sindbis virus, Coxsackie virus B4"/>
 <result pre="and 54) or cycloalkyl (55) groups were not capable of" exact="viral" post="inhibition (Figure 6) [101]. 2-Phenylamino-1,3,4-thiadiazole derivatives 45–48 were also"/>
 <result pre="(Figure 6) [101]. 2-Phenylamino-1,3,4-thiadiazole derivatives 45–48 were also screened against" exact="herpes" post="simplex HSV-1 and HSV-2, herpes simplex virus-1 TK-KOS ACV,"/>
 <result pre="45–48 were also screened against herpes simplex HSV-1 and HSV-2," exact="herpes" post="simplex virus-1 TK-KOS ACV, Sindbis virus, Coxsackie virus B4"/>
 <result pre="replication of some DNA viruses such as adenovirus Ad17 and" exact="herpes" post="simplex HSV-1 and RNA viruses such as Poliovirus 1,"/>
 <result pre="106 human aneuploid HEp-2 cells that were infected with 10" exact="infectious" post="units per cell. Derivative 56 was highly active against"/>
 <result pre="units per cell. Derivative 56 was highly active against all" exact="viral" post="strains, significantly reducing viral replication at a concentration of"/>
 <result pre="56 was highly active against all viral strains, significantly reducing" exact="viral" post="replication at a concentration of 50 μg/mL. The best"/>
 <result pre="the authors assume that compound 56 may act on the" exact="viral" post="structural proteins preventing the assembly of virus particles [102]."/>
 <result pre="μg/mL, while ethyl derivative 59 was completely inactive against all" exact="viral" post="strains (Table 7). These results suggest the importance of"/>
 <result pre="are nucleoside analogs that act by suppressing the synthesis of" exact="viral" post="DNA or RNA which leads to inhibition of virus"/>
 <result pre="61–64 [105]. The antiviral activity was evaluated in vitro against" exact="viral" post="strains parasitizing Chenopodium amaranticolor. The ability of derivatives 61–64"/>
 <result pre="Chenopodium amaranticolor. The ability of derivatives 61–64 to control the" exact="viral infection" post="of Chenopodium amaranticolor leaves was studied at two concentrations:"/>
 <result pre="amaranticolor. The ability of derivatives 61–64 to control the viral" exact="infection" post="of Chenopodium amaranticolor leaves was studied at two concentrations:"/>
 <result pre="and 100 ppm. Generally, the compounds showed good rates of" exact="viral infection" post="control at 1000 ppm. The best results were observed"/>
 <result pre="100 ppm. Generally, the compounds showed good rates of viral" exact="infection" post="control at 1000 ppm. The best results were observed"/>
 <result pre="derivatives that have been evaluated for antiviral activity against several" exact="viral" post="strains. In addition to the 2-amino-1,3,4-thiadiazole moiety, antiviral activity"/>
 <result pre="of new medicines as an alternative to the treatment of" exact="viral" post="infections. Funding This research received no external funding. Conflicts"/>
 <result pre="the treatment of viral infections. Funding This research received no" exact="external" post="funding. Conflicts of Interest The author declares no conflicts"/>
 <result pre="Wolters KluwerBaltimore, MD, USA201312741302 4.BerzofskyJ.A.AhlersJ.D.JanikJ.MorrisJ.OhS.K.TerabeM.BelyakovI.M.Progress on new vaccine strategies against" exact="chronic" post="viral infectionsJ. Clin. Invest.200411445046210.1172/JCI20042267415314679 5.collab: World Health OrganizationHuman papillomavirus"/>
 <result pre="KluwerBaltimore, MD, USA201312741302 4.BerzofskyJ.A.AhlersJ.D.JanikJ.MorrisJ.OhS.K.TerabeM.BelyakovI.M.Progress on new vaccine strategies against chronic" exact="viral" post="infectionsJ. Clin. Invest.200411445046210.1172/JCI20042267415314679 5.collab: World Health OrganizationHuman papillomavirus vaccines:"/>
 <result pre="virus activity of new 1,2,4-triazol-2-yl- and1,3,4-oxadiazol-2-yl-2-pyridinone derivativesZ. Naturforsch.200863c66767410.1515/znc-2008-9-101019040105 7.TonelliM.CicheroE.Fight against" exact="H1N1 Influenza" post="A virus: recent insights towards the development of druggable"/>
 <result pre="Human HealthShuklaR.P.MishraR.S.TripathiA.D.YadavA.K.TiwariM.MishraR.R.Bharti PublicationNew Delhi, India2017100126 17.RajputA.P.KankhareA.R.Synthetic utility of azaheterocycles: A" exact="short" post="reviewInt. J. Pharm. Sci. Invent.201761925 18.De ClercqE.LiG.Approved antiviral drugs"/>
 <result pre="yearsClin. Microbiol. Rev.20162969574710.1128/CMR.00102-1527281742 19.RazonableR.R.Antiviral drugs for viruses other than human" exact="immunodeficiency" post="virusMayo Clin. Proc.2011861009102610.4065/mcp.2011.030921964179 20.SerbanG.StanaselO.SerbanE.BotaS.2-Amino-1,3,4-thiadiazole as a potential scaffold for"/>
 <result pre="shows single-agent antitumor activity and enhances the efficacy of chemotherapeuticsMol." exact="Cancer" post="Ther.201992993300210.1158/1535-7163.MCT-10-0548 25.DawoodK.M.FarghalyT.A.Thiadiazole inhibitors: A patent reviewExpert Opin. Ther. Pat.20172747750510.1080/13543776.2017.127257527976971"/>
 <result pre="and DMSO solutionsJ. Mol. Liq.201520313714210.1016/j.molliq.2015.01.002 38.SerbanG.2-Amino-1,3,4-thiadiazoles as prospective agents in" exact="trypanosomiasis" post="and other parasitosesActa Pharm.20207025929010.2478/acph-2020-003132074064 39.SerbanG.5-Arylamino-1,3,4-thiadiazol-2-yl acetic acid esters as"/>
 <result pre="antituberculosis and antiviral agentsMarmara Pharm. J.2015198810210.12991/mpj.2015199639 50.WitF.W.N.M.LangeJ.M.A.VolberdingP.A.New HIV Drug DevelopmentGlobal" exact="HIV/AIDS" post="MedicineVolberdingP.A.SandeM.A.GreeneW.C.LangeJ.M.A.ElsevierPhiladelphia, PA, USA2008123134 51.SchillerD.S.Youssef-BesslerM.Etravirine: A second-generation nonnucleoside reverse transcriptase"/>
 <result pre="online: https://investors.merck.com/news/press-release-details/2019/Mercks-PIFELTRO-doravirine-and-DELSTRIGO-doravirinelamivudinetenofovir-disoproxil-fumarate-Receive-US-FDA-Approval-for-Use-in-Appropriate-Adults-Living-with-HIV-1-Who-Are-Virologically-Suppressed/default.aspx(accessed on 6 November 2019) 58.MargolisD.A.EronJ.J.DeJesusE.WhiteS.WannamakerP.StancilB.JohnsonM.Unexpected finding of delayed-onset" exact="seizures" post="in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation"/>
 <result pre="versus efavirenz in antiretroviral treatment-naive HIV-1 infected patients: week 48" exact="primary" post="analysis results from an ongoing, multicenter, randomized, double-blind, Phase"/>
 <result pre="IIb trialJ. Acquir. Immune Defic. Syndr.20136217117910.1097/QAI.0b013e31827a2ba223328090 60.PlattenM.FatkenheuerG.Lersavirine—a new drug for" exact="HIV infection" post="therapyExpert. Opin. Investig. Drugs2013221687169410.1517/13543784.2013.846325 61.SacksD.LedwabaJ.MorrisL.HuntG.M.Rapid detection of common HIV-1"/>
 <result pre="trialJ. Acquir. Immune Defic. Syndr.20136217117910.1097/QAI.0b013e31827a2ba223328090 60.PlattenM.FatkenheuerG.Lersavirine—a new drug for HIV" exact="infection" post="therapyExpert. Opin. Investig. Drugs2013221687169410.1517/13543784.2013.846325 61.SacksD.LedwabaJ.MorrisL.HuntG.M.Rapid detection of common HIV-1"/>
 <result pre="patterns of the reverse transcriptase and protease genes in Human" exact="Immunodeficiency" post="Virus type 1-infected patients undergoing combination therapy: survey of"/>
 <result pre="Med. Chem. Lett.2008185368537110.1016/j.bmcl.2008.09.05518824350 70.ZhangZ.XuW.KohY.H.ShimJ.H.GirardetJ.L.YehL.T.HamatakeR.K.HongZ.A novel non-nucleoside analogue that inhibits human" exact="immunodeficiency" post="virus type 1 isolates resistant to current non-nucleoside reverse"/>
 <result pre="Lett.2008185368537110.1016/j.bmcl.2008.09.05518824350 70.ZhangZ.XuW.KohY.H.ShimJ.H.GirardetJ.L.YehL.T.HamatakeR.K.HongZ.A novel non-nucleoside analogue that inhibits human immunodeficiency virus" exact="type 1" post="isolates resistant to current non-nucleoside reverse transcriptase inhibitorsAntimicrob. Agents"/>
 <result pre="metabolism and its physiological importanceJ. Parenter. Enteral. Nutr.19901440S44S10.1177/0148607190014004022205730 75.BromleyS.D.BennettM.K.GrossM.I.LiJ.ChenL.GoyalB.LaidigG.StantonT.F.SjogrenE.B.Treatment of" exact="viral" post="infections with inhibitors of glutaminasePCT Int. Appl.PCT/US2014/061746; WO 2015/061432"/>
 <result pre="and its physiological importanceJ. Parenter. Enteral. Nutr.19901440S44S10.1177/0148607190014004022205730 75.BromleyS.D.BennettM.K.GrossM.I.LiJ.ChenL.GoyalB.LaidigG.StantonT.F.SjogrenE.B.Treatment of viral" exact="infections" post="with inhibitors of glutaminasePCT Int. Appl.PCT/US2014/061746; WO 2015/061432 A12015"/>
 <result pre="glutaminaseJ. Neurochem.200710253954910.1111/j.1471-4159.2007.04594.x17596215 79.BabayoA.ThairuY.NasirI.A.BabaM.M.Serological evidence and sociodemographic risk factors of recent" exact="cytomegalovirus infection" post="in pregnant women attending a tertiary hospital in Maiduguri,"/>
 <result pre="Neurochem.200710253954910.1111/j.1471-4159.2007.04594.x17596215 79.BabayoA.ThairuY.NasirI.A.BabaM.M.Serological evidence and sociodemographic risk factors of recent cytomegalovirus" exact="infection" post="in pregnant women attending a tertiary hospital in Maiduguri,"/>
 <result pre="Merck and Co., Inc.Whitehouse Station, NJ, USA20031164 82.collab: Centers for" exact="Disease" post="Control and PreventionCytomegalovirus (CMV) and Congenital CMV InfectionAvailable online:"/>
 <result pre="USA20031164 82.collab: Centers for Disease Control and PreventionCytomegalovirus (CMV) and" exact="Congenital" post="CMV InfectionAvailable online: https://www.cdc.gov/cmv/overview.html(accessed on 11 July 2018) 83.TanB.H.Cytomegalovirus"/>
 <result pre="84.McGavinJ.K.GoaK.L.Ganciclovir: An update of its use in the prevention of" exact="cytomegalovirus infection" post="and disease in transplant recipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 85.SakamotoH.HiranoM.NoseK.UenoS.OkiT.SugimotoK.NishiokaT.KusunokiS.NakamuraY.A case of severe"/>
 <result pre="An update of its use in the prevention of cytomegalovirus" exact="infection" post="and disease in transplant recipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 85.SakamotoH.HiranoM.NoseK.UenoS.OkiT.SugimotoK.NishiokaT.KusunokiS.NakamuraY.A case of severe"/>
 <result pre="of its use in the prevention of cytomegalovirus infection and" exact="disease" post="in transplant recipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 85.SakamotoH.HiranoM.NoseK.UenoS.OkiT.SugimotoK.NishiokaT.KusunokiS.NakamuraY.A case of severe ganciclovir-induced encephalopathyCase"/>
 <result pre="treatment of CMV infectionsUS Patent6,150,3852000 87.collab: World Health OrganizationBattle against" exact="Respiratory" post="Viruses (BRaVe) initiativeAvailable online: http://www.who.int/influenza/patient_care/clinical/ brave/en/(accessed on 14 June"/>
 <result pre="2018) 88.collab: World Health OrganizationResearch needs for the battle against" exact="respiratory" post="viruses (BRAve). Background document 2013Available online: http://www.who.int/influenza/patient_care/clinical/BRaVe _ Research_Agenda"/>
 <result pre="Research_Agenda _ 2013.pdf(accessed on 14 June 2018) 89.BellosA.MulhollandK.O’BrienK.L.QaziS.A.GayerM.ChecchilF.The burden of" exact="acute" post="respiratory infections in crisis-affected populations: A systematic reviewConfl. Health2010411210.1186/1752-1505-4-320181042"/>
 <result pre="_ 2013.pdf(accessed on 14 June 2018) 89.BellosA.MulhollandK.O’BrienK.L.QaziS.A.GayerM.ChecchilF.The burden of acute" exact="respiratory" post="infections in crisis-affected populations: A systematic reviewConfl. Health2010411210.1186/1752-1505-4-320181042 90.StraliottoS.M.SiqueiraM.M.MullerR.L.FischerG.B.CunhaM.L.T.NestorS.M.Viral"/>
 <result pre="2013.pdf(accessed on 14 June 2018) 89.BellosA.MulhollandK.O’BrienK.L.QaziS.A.GayerM.ChecchilF.The burden of acute respiratory" exact="infections" post="in crisis-affected populations: A systematic reviewConfl. Health2010411210.1186/1752-1505-4-320181042 90.StraliottoS.M.SiqueiraM.M.MullerR.L.FischerG.B.CunhaM.L.T.NestorS.M.Viral etiology"/>
 <result pre="in crisis-affected populations: A systematic reviewConfl. Health2010411210.1186/1752-1505-4-320181042 90.StraliottoS.M.SiqueiraM.M.MullerR.L.FischerG.B.CunhaM.L.T.NestorS.M.Viral etiology of" exact="acute" post="respiratory infections among children in Porto Alegre, RS, BrazilRev."/>
 <result pre="crisis-affected populations: A systematic reviewConfl. Health2010411210.1186/1752-1505-4-320181042 90.StraliottoS.M.SiqueiraM.M.MullerR.L.FischerG.B.CunhaM.L.T.NestorS.M.Viral etiology of acute" exact="respiratory" post="infections among children in Porto Alegre, RS, BrazilRev. Soc."/>
 <result pre="populations: A systematic reviewConfl. Health2010411210.1186/1752-1505-4-320181042 90.StraliottoS.M.SiqueiraM.M.MullerR.L.FischerG.B.CunhaM.L.T.NestorS.M.Viral etiology of acute respiratory" exact="infections" post="among children in Porto Alegre, RS, BrazilRev. Soc. Bras."/>
 <result pre="BrazilRev. Soc. Bras. Med. Tro.20023528329110.1590/S0037-8682200200040000212170321 91.Da SilvaR.C.da Silva MendesG.RojasM.A.AmorimA.R.CouceiroJ.N.LupiO.ElabrasJ.PiresG.ValleS.SantosN.Frequency of" exact="viral" post="etiology in symptomatic adult upper respiratory tract infectionsBraz. J."/>
 <result pre="Med. Tro.20023528329110.1590/S0037-8682200200040000212170321 91.Da SilvaR.C.da Silva MendesG.RojasM.A.AmorimA.R.CouceiroJ.N.LupiO.ElabrasJ.PiresG.ValleS.SantosN.Frequency of viral etiology in" exact="symptomatic" post="adult upper respiratory tract infectionsBraz. J. Infect. Dis.201519303510.1016/j.bjid.2014.08.00525307684 92.FendrickA.M.MontoA.S.NightengaleB.SarnesM.The"/>
 <result pre="Tro.20023528329110.1590/S0037-8682200200040000212170321 91.Da SilvaR.C.da Silva MendesG.RojasM.A.AmorimA.R.CouceiroJ.N.LupiO.ElabrasJ.PiresG.ValleS.SantosN.Frequency of viral etiology in symptomatic" exact="adult" post="upper respiratory tract infectionsBraz. J. Infect. Dis.201519303510.1016/j.bjid.2014.08.00525307684 92.FendrickA.M.MontoA.S.NightengaleB.SarnesM.The economic"/>
 <result pre="91.Da SilvaR.C.da Silva MendesG.RojasM.A.AmorimA.R.CouceiroJ.N.LupiO.ElabrasJ.PiresG.ValleS.SantosN.Frequency of viral etiology in symptomatic adult" exact="upper" post="respiratory tract infectionsBraz. J. Infect. Dis.201519303510.1016/j.bjid.2014.08.00525307684 92.FendrickA.M.MontoA.S.NightengaleB.SarnesM.The economic burden"/>
 <result pre="SilvaR.C.da Silva MendesG.RojasM.A.AmorimA.R.CouceiroJ.N.LupiO.ElabrasJ.PiresG.ValleS.SantosN.Frequency of viral etiology in symptomatic adult upper" exact="respiratory" post="tract infectionsBraz. J. Infect. Dis.201519303510.1016/j.bjid.2014.08.00525307684 92.FendrickA.M.MontoA.S.NightengaleB.SarnesM.The economic burden of"/>
 <result pre="tract infectionsBraz. J. Infect. Dis.201519303510.1016/j.bjid.2014.08.00525307684 92.FendrickA.M.MontoA.S.NightengaleB.SarnesM.The economic burden of non-influenza-related" exact="viral" post="respiratory tract infections in the United StatesArch. Intern. Med.200316348749410.1001/archinte.163.4.48712588210"/>
 <result pre="infectionsBraz. J. Infect. Dis.201519303510.1016/j.bjid.2014.08.00525307684 92.FendrickA.M.MontoA.S.NightengaleB.SarnesM.The economic burden of non-influenza-related viral" exact="respiratory" post="tract infections in the United StatesArch. Intern. Med.200316348749410.1001/archinte.163.4.48712588210 93.JohnsonD.S.LiJ.J.Neuraminidase"/>
 <result pre="Infect. Dis.201519303510.1016/j.bjid.2014.08.00525307684 92.FendrickA.M.MontoA.S.NightengaleB.SarnesM.The economic burden of non-influenza-related viral respiratory tract" exact="infections" post="in the United StatesArch. Intern. Med.200316348749410.1001/archinte.163.4.48712588210 93.JohnsonD.S.LiJ.J.Neuraminidase inhibitors for"/>
 <result pre="(DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and" exact="respiratory" post="syncytial virusEur. J. Med. Chem.201713546747810.1016/j.ejmech.2017.04.07028477572 96.FrancesconiV.GiovanniniL.SantucciM.CicheroE.CostiM.P.NaesensL.GiordanettoF.TonelliM.Synthesis, biological evaluation and"/>
 <result pre="World Health OrganizationFact sheets on sustainable development goals: health target," exact="Viral hepatitis," post="World Health Organization 2017, Copenhagen, Denmark, www.euro.who.int/sdgsAvailable online: http://www.euro.who.int/__data/assets/pdf_file/0003/348222/Fact-sheet-SDG-viral-hepatitis-FINAL-en.pdf?ua=1(accessed"/>
 <result pre="C treatmentsAvailable online: https://www.fda.gov/patients/hepatitis-b-c/ hepatitis-b-and-c-treatments(accessed on 23 January 2020) 100.KurkelaS.RattiO.HuhtamoE.UzcateguiN.NuortiJ.P.LaakkonenJ.ManniT.HelleP.VaheriA.VapalahtiO.Sindbis" exact="virus infection" post="in resident birds, migratory birds, and humans, FinlandEmerg. Infect."/>
 <result pre="treatmentsAvailable online: https://www.fda.gov/patients/hepatitis-b-c/ hepatitis-b-and-c-treatments(accessed on 23 January 2020) 100.KurkelaS.RattiO.HuhtamoE.UzcateguiN.NuortiJ.P.LaakkonenJ.ManniT.HelleP.VaheriA.VapalahtiO.Sindbis virus" exact="infection" post="in resident birds, migratory birds, and humans, FinlandEmerg. Infect."/>
 <result pre="6 The influence of substituents of 1,3,4-thiadiazole derivatives 50–55 on" exact="viral" post="inhibition. Figure 7 The influence of substituents of 1,3,4-thiadiazole"/>
 <result pre="vitro cytotoxicity of compounds 45–48 (adapted from [49]). Influenza A" exact="H1N1 Influenza" post="A H3N2 Para Influenza-3 Reovirus-1 Feline Coronavirus EC50 (μM)"/>
 <result pre="antiviral activity of compounds 61–64 (adapted from [105]). R’ R" exact="Viral Infection" post="Control (%) 1000 ppm 100 ppm 61 4-CH3O D-glucopentyl"/>
 <result pre="activity of compounds 61–64 (adapted from [105]). R’ R Viral" exact="Infection" post="Control (%) 1000 ppm 100 ppm 61 4-CH3O D-glucopentyl"/>
</results>
